Project Description

Sirga is an early-phase drug discovery company focused on novel targets of pathogens (bacterial, fungal and viral) that are difficult for the pathogenic organism to alter, thus reducing the potential for drug resistance.

Sirga has successfully developed a proprietary High-throughput screen to identify a new class of HIV drugs that will be less likely to elicit drug resistance. Sirga is currently developing small molecules that block a targeted control of HIV replication. Unlike the mechanisms of action of all other drugs approved or in clinical trials to treat HIV, Sirga’s targets are RNA/protein interactions of HIV infected human cells that (1) do not occur in non-infected cells; (2) are critical to viral replication; (3) would be extremely difficult for the virus to develop resistance to drug intervention; and (4) are unique to Sirga.